Page 1

ANNOUNCEMENT NO . 214 4 November 2021 Trading statement for Q1 2021/22 ( 1 July - 30 September 2021 ) Significant growth in revenue and EBITDA ChemoMetec continued its growth trend in Q1 2021/22 , generating revenue of DKK 85.0 million , a 33 % increase on the year - earlier period . The company recorded improvements in all regions and in all product segments . The US market provided the strongest improve ment , driven primarily by high growth rates within cell - based therapy . The Q1 EBITDA was DKK 43.4 million , corresponding to a 41 % increase , and the EBITDA margin was 51 % against 48 % in the year - earlier period . Highlights Revenue amounted to DKK 85.0 million in Q1 2021/22 , a 33 % increase on the year earlier period . ■ chemometec ■ ■ Much of the revenue improvement was due to a 37 % increase in the North American market , which now accounts for 54 % of ChemoMetec's consolidated revenue . Revenue in ChemoMetec's core business area , Life science research , Cell - based therapy and Bioprocessing ( LCB ) , increased by 34 % in Q1 to account for 92 % of the overall revenue . Given the global supply situation and the resulting component shortage , Chemo Metec expects a few months ' delay in the completion of XcytoMatic , the new high speed cell counter , from the end of 2021 to April 2022 . The global supply situation for raw materials has not yet impacted ChemoMetec's ability to supply its finished products , but there are growing concerns about the fu ture supply situation should the global component shortage continue into 2022 . EBITDA increased to DKK 43.4 million in Q1 , up from DKK 30.8 million in the year earlier period , corresponding to an increase of 41 % . The EBITDA margin was 51 % , against 48 % in the same period of last year . ChemoMetec reconfirms the FY 2021/22 guidance recently raised on 27 October 2021 . ChemoMetec A / S Gydevang 43 DK - 3450 Allerod Denmark Phone +45 4813 1020 Fax +45 4813 1021 www.chemometec.com CVR.No. 1982.8131